Drug Database · Clinicians

Rebamipide

Brands (5) Mucopid, Mucopro, MUCOSTA…Show all

MUCOSAL PROTECTANT; Antigastritis/Anti-ulcer; and others PH FDA category

Rx · Prescription drug5 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Gastric ulcer: 100 mg three times daily (morning, evening, bedtime)
  • Gastric mucosal lesions in acute gastritis or acute exacerbation of chronic gastritis: 100 mg three times daily
renalcarematters.com, reviewed

Dosing: Altered kidney function

Rebamipide is a gastric mucosal protectant; about 10% of a dose appears in urine. In kidney impairment, single-dose levels are higher and the half-life longer, but the Japanese insert reports no accumulation with repeated dosing in dialysis patients and sets no kidney dose change. It has no US FDA label.

Kidney function measure: The Japanese insert describes kidney impairment and dialysis without numeric thresholds or dose changes; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 100 mg three times daily (morning, evening and at bedtime for gastric ulcer) (PMDA insert).
CrCl 30–59 mL/min
The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
CrCl 15–29 mL/min
The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
CrCl <15 mL/min (not on dialysis)
The Japanese insert gives no dose change and has no kidney-impairment caution section (no section 9.2). Levels were higher and the half-life longer after a single 100 mg dose in kidney impairment; steady-state levels in dialysis patients matched single-dose predictions, so no accumulation is expected (PMDA insert 16.6.1).
Hemodialysis (intermittent)
No dose change; steady-state levels in dialysis patients matched single-dose predictions (no accumulation) (PMDA insert).
Peritoneal dialysis
No PD data.
CRRT
No data.
  • Dialyzable? Not stated (98.4% to 98.6% protein-bound).
  • Monitoring Liver tests and blood counts if symptoms (hepatic dysfunction, jaundice, leukopenia, thrombocytopenia reported); stop if marked transaminase rise with fever and rash (PMDA insert).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: PMDA (Japan) product information (October 2023). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
No pediatric trials (PMDA insert).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 100 mg
  • Tablet: 100 mg

Registered products in the Philippines

5 products registered with the Food and Drug Administration (FDA) Philippines list Rebamipide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products5
Philippine FDA-registered products for Rebamipide
Package insert
MucopidRebamipide
100 mg Film Coated TabletAlu/PVC Blister Pack of 10's Box of 100's
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Ritemed Phils., Inc.
DRP-8194
May 15, 2029
MucoproRebamipide
100 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Kyung Dong Pharm Co., Ltd.Republic of Korea
Kaufmann Pharma Inc.
DRP-3797
May 9, 2031
MUCOSTAREBAMIPIDE
100 mg TABLET
Rx
KOREA OTSUKA PHARMACEUTICAL CO., LTD.
—
DRP-6291
Nov 21, 2026
Rebamid 100Rebamipide
100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY48673
Jun 6, 2028
RemastaRebamipide
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Myungmoon Pharm. Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.
DR-XY42872
Oct 25, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Adverse reactions

Common

  • Rash, pruritus
  • Constipation, bloating, diarrhea, nausea

Serious

  • Shock, anaphylaxis
  • Leukopenia, thrombocytopenia
  • Hepatic dysfunction, jaundice
renalcarematters.com, reviewed

Monitoring parameters

  • Liver tests and blood counts if symptoms (hepatic dysfunction, jaundice, leukopenia, thrombocytopenia reported); stop if marked transaminase rise with fever and rash (PMDA insert). Kidney
  • Liver tests and blood counts if symptomatic
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peak2.4 hours (100 mg fasting)
Half-life1.9 hours
Half-life in kidney failure (ESKD) kidneyProlonged after a single dose; no accumulation on dialysis
Protein binding98.4% to 98.6%
Metabolism (CYP, transporters)Minimal (8-hydroxy metabolite about 0.03%; CYP3A4 in vitro)
Renal excretion kidneyAbout 10% of a dose in urine, mostly unchanged
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Pharmaceuticals and Medical Devices Agency (Japan). Rebamipide tablets 100 mg "NP" package insert [PMDA (Japan) product information, October 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190646606
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Nipro Corporation. (2023). Rebamipide tablets 100 mg "NP" [Japanese package insert, 1st edition, revised October 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190646606

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .